Aprepitant added to cough suppressant reduces cough severity in advanced lung cancer

  • Noronha V & al.
  • Chest
  • 17 Jan 2020

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with advanced lung cancer and cough who received aprepitant plus a cough suppressant reported significantly greater cough relief than those treated with cough suppressant alone.

Why this matters

Study design

  • Randomized controlled trial.
  • 128 patients with advanced lung cancer and cough that had persisted for >2 weeks despite use of cough suppressant received either aprepitant plus physician’s choice of cough suppressant (n=64) or physician’s choice of cough medication alone (n=64) for 7 days.
  • Funding: Tata Memorial Center Research Administration Council; others.

Key results

  • Mean visual analog scale scores decreased significantly more from baseline to 9 days after treatment initiation with aprepitant+suppressant:
    • From 67.68 to 38.5 mm with aprepitant+suppressant vs from 62.2 to 48.57 mm with suppressant only (P<.001>
  • Mean Manchester Cough in Lung Cancer Scale scores decreased significantly more from baseline to 9 days after treatment initiation with aprepitant+suppressant:
    • From 33.06 to 25.17 with the combination vs from 29.64 to 23 with suppressant only (P<.001>
  • The aprepitant group also had a significant improvement in cough-specific QoL questions (P=.017).
  • No significant difference between groups in adverse events.

Limitations

  • Single-center study with no placebo group.